文摘
Agonists of liver X receptors (LXR) 伪 and 尾 are important regulators of cholesterol metabolism, but agonism of the LXR伪 subtype appears to cause hepatic lipogenesis, suggesting LXR尾-selective activators are attractive new lipid lowering drugs. In this work, pharmacophore modeling and shape-based virtual screening were combined to predict new LXR尾-selective ligands. Out of the 10 predicted compounds, three displayed significant LXR activity. Two activated both LXR subtypes. The third compound activated LXR尾 1.8-fold over LXR伪.